WuXi Biologics (Cayman) Past Earnings Performance
Past criteria checks 2/6
WuXi Biologics (Cayman) has been growing earnings at an average annual rate of 33.4%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 37.3% per year. WuXi Biologics (Cayman)'s return on equity is 8.1%, and it has net margins of 20%.
Key information
33.4%
Earnings growth rate
31.5%
EPS growth rate
Life Sciences Industry Growth | 41.4% |
Revenue growth rate | 37.3% |
Return on equity | 8.1% |
Net Margin | 20.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease
Aug 02Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Jun 29What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
May 16Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today
May 03Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Apr 21An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 42% Undervalued
Mar 26Why We're Not Concerned Yet About WuXi Biologics (Cayman) Inc.'s (HKG:2269) 30% Share Price Plunge
Feb 09Revenue & Expenses BreakdownBeta
How WuXi Biologics (Cayman) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 17,034 | 3,400 | 2,086 | 786 |
30 Sep 23 | 16,794 | 3,776 | 2,021 | 769 |
30 Jun 23 | 16,554 | 4,152 | 1,956 | 753 |
31 Mar 23 | 15,911 | 4,286 | 1,824 | 718 |
31 Dec 22 | 15,269 | 4,420 | 1,693 | 683 |
30 Sep 22 | 14,179 | 4,251 | 1,472 | 670 |
30 Jun 22 | 13,090 | 4,081 | 1,251 | 657 |
31 Mar 22 | 11,690 | 3,735 | 1,192 | 579 |
31 Dec 21 | 10,290 | 3,388 | 1,133 | 502 |
30 Sep 21 | 9,183 | 3,092 | 1,043 | 398 |
30 Jun 21 | 8,075 | 2,795 | 952 | 295 |
31 Mar 21 | 6,844 | 2,242 | 837 | 299 |
31 Dec 20 | 5,612 | 1,689 | 722 | 304 |
30 Sep 20 | 4,967 | 1,494 | 648 | 289 |
30 Jun 20 | 4,321 | 1,300 | 574 | 275 |
31 Mar 20 | 4,152 | 1,157 | 512 | 267 |
31 Dec 19 | 3,984 | 1,014 | 451 | 260 |
30 Sep 19 | 3,535 | 922 | 427 | 241 |
30 Jun 19 | 3,087 | 831 | 404 | 222 |
31 Mar 19 | 2,811 | 731 | 365 | 196 |
31 Dec 18 | 2,534 | 631 | 326 | 169 |
30 Sep 18 | 2,277 | 520 | 270 | 132 |
30 Jun 18 | 2,019 | 410 | 214 | 94 |
31 Mar 18 | 1,819 | 331 | 195 | 84 |
31 Dec 17 | 1,619 | 253 | 175 | 74 |
30 Sep 17 | 1,429 | 177 | 155 | 66 |
30 Jun 17 | 1,233 | 149 | 128 | 60 |
31 Mar 17 | 1,111 | 145 | 119 | 56 |
31 Dec 16 | 989 | 141 | 110 | 53 |
30 Sep 16 | 889 | 171 | 101 | 61 |
31 Dec 15 | 557 | 45 | 86 | 40 |
31 Dec 14 | 332 | 42 | 48 | 35 |
Quality Earnings: 2269 has high quality earnings.
Growing Profit Margin: 2269's current net profit margins (20%) are lower than last year (29%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2269's earnings have grown significantly by 33.4% per year over the past 5 years.
Accelerating Growth: 2269's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2269 had negative earnings growth (-23.1%) over the past year, making it difficult to compare to the Life Sciences industry average (0.7%).
Return on Equity
High ROE: 2269's Return on Equity (8.1%) is considered low.